StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities researchers at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on MRNS. HC Wainwright reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Cantor Fitzgerald decreased their target price on shares of Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Trading Up 8.3 %

NASDAQ MRNS opened at $0.33 on Friday. The firm has a market capitalization of $18.06 million, a P/E ratio of -0.12 and a beta of 1.27. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The firm’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $1.39.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period last year, the firm earned ($0.61) earnings per share. As a group, sell-side analysts predict that Marinus Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently modified their holdings of MRNS. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after acquiring an additional 990,607 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Marinus Pharmaceuticals during the 1st quarter worth about $384,000. SG Americas Securities LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $34,000. Finally, Values First Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.